Insilico's services accelerate the bioprocess development for new molecules from cell line engineering to manufacturing for the biopharmaceutical industry.

We use our broad know-how to support Insilico's clients in making the right decision and enable them to reduce development timelines and improve the production of their therapeutic proteins.

In the course of creating a Digital Twin physical bioprocesses are converted into smart virtual representations. These are able to run countless simulations of your process to identify those parameters which will have the greatest improvement potential for the chosen stage of the bioprocess value chain.

As a result Insilico's customers receive detailed recommendations for intensifying their process for increased productivity and robust product quality.

It is essential to have a high degree of knowledge and understanding of the behaviour of living organisms in a bioprocess to deliver these services. Therefore our interdisciplinary team includes highly educated experts skilled in biochemistry, bioprocess engineering, mathematics, data and computer science.

We combine our expert knowledge with the power of genome-based metabolic networks and artificial intelligence to create predictive Digital Twins for various use cases in the process development value chain.

Discuss your needs with us and realize the potential of Insilico's services for reaching your optimization objectives.

Identification of Multiple Gene Targets Increase product yield and productivity

Significant improvements in bioprocesses with regard to product yield or product titre can only be achieved with metabolic engineering and by balancing changes in the expression levels of multiple target genes accurately. By automatic simulation of hundreds of thousands of different expression scenarios, Insilico is able to identify and prioritize the most promising gene target combinations. For each target gene, Insilico provides recommendations stipulating whether it should be over-expressed, deleted or attenuated in an expression scenario, and to which degree. This approach has a proven track record for increased cell productivity within shorter time and with less experimental effort compared to traditional optimisation techniques. In contrast to undirected mutagenesis, our rational computational strategy has the advantage that our customers know what has changed inside their production cells, so that they can transform this know-how into Intellectual Property. Moreover, Insilico’s strategy facilitates the optimization of strains for which mutagenesis techniques fail to result in further strain improvement.

Design of Novel Metabolic Pathways Develop innovative bioprocesses

Insilico Biotechnology designs innovative synthesis routes for already existing biotechnological products as well as synthesis pathways for new bioproducts using a wide range of production hosts including, mammalian cells such as CHO and HEK cells as well as microbial cells such as Escherichia coli. Host metabolism is augmented in silico using our proprietary reaction database containing more than 8,000 enzymatic and non-enzymatic reactions. The resulting “supernetworks” are screened on high performance computer clusters for novel biochemical pathway solutions leading to the desired product. In many cases, these novel metabolic pathways are eligible for patenting. Let us know your host cell organism and goal and we will be happy to make an offer.

Clone Selection Shorten timelines and save experimental resources

Many of today's bioproduction processes are designed to produce similar products on the same platform and/or using a standardized production process, especially for producing recombinant proteins. Here, the early choice of a suitable production clone which performs robustly in a given process format is the key to accelerating process development and reducing time to market. Insilico Biotechnology makes an early selection of production clones possible by providing an extensive range of indicators charactering clone performance based on cell culture data collected in scale-down cultivation systems in the customer’s facility. These include time-resolved indicators not only for cell growth and product synthesis, but also for metabolic efficiency, intracellular fluxes and byproduct formation. This form of comprehensive characterization provides a sound basis for detecting promising robust candidate clones for large-scale production early during clone assessment. The method further reduces the risk of overlooking good producers at early stages and of propagating poor candidates for too long along the process development pipeline, ultimately saving costly time and resources.

Media Design and Feeding Strategies Speed up process development and increase product titre and quality

Insilico Biotechnology improves process performance by aligning nutrient supply exactly with the true demand of the production cells. Mismatches between cellular nutrient demand and available supply, due to either nutrient limitation or overfeeding, often result in poor process performance such as slow growth, reduced productivity or excessive byproduct formation. Insilico Biotechnology develops optimized feed media compositions and improved feeding strategies tailored to the actual nutrient demand in each process phase by simulating and evaluating millions of process scenarios on our high performance computing platform. These optimized media and feeding schemes increase process performance by yielding higher product titres, improving growth and reducing byproduct formation. By controlling the production process, the heterogeneity of a product can be controlled. We develop and implement optimized media and feeding conditions to enable controlled and directed product quality including robust glycosylation profiles, desired charge variants of a product and other quality attributes related to process conditions.

Technology Transfer Increase your capacity to deliver optimized processes for new therapeutic proteins

We enable our customers to use predictive Digital Twins in-house by individual training sessions and consulting engagements. Modelling and simulation experience is not required to run Insilico's easy-to-use workflow solutions and generate predictions for your optimization objectives. Insilico's Technology Platform will scale with your needs based on a modular cloud architecture. The transfer of Insilico’s Digital Twins in your process development workflow will significantly increase your capacity to deliver optimized processes for new therapeutic proteins.